Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 137, Issue 6, Pages 1498-1502
Publisher
Wiley
Online
2015-02-24
DOI
10.1002/ijc.29496
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic Significance of Beclin-1 Expression in Colorectal Cancer: a Meta-analysis
- (2014) Ye Han et al. Asian Pacific Journal of Cancer Prevention
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Beclin 1 and UVRAG Confer Protection from Radiation-Induced DNA Damage and Maintain Centrosome Stability in Colorectal Cancer Cells
- (2014) Jae Myung Park et al. PLoS One
- JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy
- (2014) Xinbing Sui et al. Scientific Reports
- Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy
- (2013) Jae Myung Park et al. CANCER BIOLOGY & THERAPY
- Autophagy-related proteins LC3 and Beclin-1 impact the efficacy of chemoradiation on esophageal squamous cell carcinoma
- (2013) Yongshun Chen et al. PATHOLOGY RESEARCH AND PRACTICE
- Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal Cancer
- (2012) In Ja Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now: Table 1
- (2012) Tom P MacGregor et al. JOURNAL OF CLINICAL PATHOLOGY
- Pathological grading of regression: an International Study Group perspective
- (2012) Runjan Chetty et al. JOURNAL OF CLINICAL PATHOLOGY
- Chloroquine or Chloroquine-PI3K/Akt Pathway Inhibitor Combinations Strongly Promote γ-Irradiation-Induced Cell Death in Primary Stem-Like Glioma Cells
- (2012) Elke Firat et al. PLoS One
- Identification of a Biomarker Profile Associated With Resistance to Neoadjuvant Chemoradiation Therapy in Rectal Cancer
- (2011) Julio Garcia-Aguilar et al. ANNALS OF SURGERY
- Endorectal ultrasound in rectal carcinoma – do the literature results really correspond to the realities of routine clinical care?
- (2011) F. Marusch et al. ENDOSCOPY
- The Role of Autophagy in Cancer: Therapeutic Implications
- (2011) Z. J. Yang et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model
- (2010) Jie Li et al. EUROPEAN JOURNAL OF CANCER
- High Ki67, Bax and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction
- (2009) M Kikuchi et al. BRITISH JOURNAL OF CANCER
- Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
- (2009) David Sebag-Montefiore et al. LANCET
- The autophagy effector Beclin 1: a novel BH3-only protein
- (2009) S Sinha et al. ONCOGENE
- Prognostic Impact of Bim, Puma, and Noxa Expression in Human Colon Carcinomas
- (2008) F. A. Sinicrope et al. CLINICAL CANCER RESEARCH
- Prognostic Value of Pathologic Complete Response After Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Long-Term Analysis of 566 ypCR Patients
- (2008) Carlo Capirci et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More